Celldex Therapeutics Stock - UBS reiterates Buy after data update
17.06.2026 - 21:50:03 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:40 UTC. Details in the imprint.
Celldex Therapeutics (US15117B1035) drew renewed analyst attention this week. UBS reiterated its Buy rating and $45.00 price target after updated clinical trial data were presented, according to an analyst-ratings summary from Investing.com.
All news and analysis on Celldex Therapeutics stock
Track current ratings, pipeline news and price data on Celldex Therapeutics in the dedicated topic area and on the company's Investor Relations page.
UBS sticks with Buy rating
According to the analyst round-up, UBS reaffirmed its positive view on Celldex after the company presented fresh clinical data, and the bank kept its $45.00 price target unchanged on the Nasdaq-listed biotech stock.
The reference notes that the reaffirmation followed updated results from Celldex's pipeline, which UBS sees as supporting the long-term investment case for the immunology-focused developer.
Wednesday focus on operations and pipeline
Operationally, Celldex remains concentrated on advancing barzolvolimab, its lead monoclonal antibody targeting the KIT receptor, across several indications such as chronic spontaneous urticaria and other inflammatory conditions.
Recent commentary highlighted that the company has completed enrollment in a global late-stage program of barzolvolimab, a key milestone for its development strategy and a crucial step toward potential registration studies.
How the company makes money
Celldex Therapeutics is a clinical-stage biotechnology company that aims to generate future revenue from barzolvolimab and other immunology candidates by out-licensing, partnerships or, upon approval, direct commercialization in select markets.
Where the stock trades today
The shares of Celldex Therapeutics (US15117B1035) trade on the Nasdaq at $30.00 as of 06/17/2026, 19:30 UTC.
Key facts on Celldex Therapeutics stock
- Company: Celldex Therapeutics Inc.
- ISIN: US15117B1035
- WKN: A1JRLH
- Ticker: CLDX
- Venue: Nasdaq
- Price (as of 06/17/2026, 19:30 UTC): 30.00 USD
- Market cap: 1,950,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of major headline indices such as the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
